PRODUCTS
SERVICES
The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.
1.93
6 yrs 8 m
0.5%
3,056.90 Crs
0.50% on or before 1M, Nil after 1M
Mid Growth
8.02
SIP 100 & Lumpsum 100
NA
Chirag Dagli
Investors understand that their principal will be at very high risk